TrialJournal of Crohn's & colitis2024

Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT Programme.

Silvio Danese et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.